Open Access

Puerarin inhibits apoptosis and inflammation in myocardial cells via PPARα expression in rats with chronic heart failure

  • Authors:
    • Le He
    • Tong Wang
    • Bing‑Wei Chen
    • Feng‑Min Lu
    • Jing Xu
  • View Affiliations

  • Published online on: September 6, 2019     https://doi.org/10.3892/etm.2019.7984
  • Pages: 3347-3356
  • Copyright: © He et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Chronic heart failure affects myocardial energy metabolism and cardiac function. Puerarin has been reported to improve cardiac function through regulation of energy metabolism in mice with myocardial infarction. The aim of the current study was to determine whether puerarin can improve body weight and reduce inflammation and apoptosis in rats with chronic heart failure. Rats were divided into three groups: Puerarin, PBS and sham group. Transverse aortic constriction was performed to induce chronic heart failure in the puerarin an PBS groups. Cardiac function, apoptosis and inflammation were evaluated following a 4‑week treatment in rats with chronic heart failure. The results demonstrated that puerarin significantly increased the survival rate of rats and improved cardiac function compared with the PBS group. In addition, puerarin decreased lactate dehydrogenase and succinate dehydrogenase activity compared with the PBS group. Puerarin treatment increased the expression levels of glucose transporter type 4 and decreased the expression levels of CD36. Additionally, puerarin decreased the levels inflammatory factors, including tumor necrosis factor α, interleukin (IL)‑1β and IL‑6 in serum and myocardial tissue compared with the PBS group. Puerarin upregulated peroxisome proliferator‑activated receptor α (PPARα) and its downstream target genes nuclear respiratory factor 1, FOS proto‑oncogene, YY1 transcription factor, acetyl‑coenzyme A carboxylase a, Fas cell surface death receptor, L‑type pyruvate kinase and acetyl‑coenzyme A dehydrogenase medium chain in myocardial cells from rats with chronic heart failure. These results demonstrated that puerarin inhibited apoptosis and inflammation in myocardial cells via the PPARα pathway. In conclusion, the present study indicated that puerarin may exhibit antiapoptotic and anti‑inflammatory activity through the PPARα pathway in rats with chronic heart failure.

References

1 

Wang Y, Li X, Li Z, Zhang Y and Wang D: YiQiFuMai injection for chronic heart failure: Protocol for a systematic review and meta-analysis. Medicine (Baltimore). 97:e99572018. View Article : Google Scholar : PubMed/NCBI

2 

Taylor KS, Verbakel JY, Feakins BG, Price CP, Perera R, Bankhead C and Plüddemann A: Diagnostic accuracy of point-of-care natriuretic peptide testing for chronic heart failure in ambulatory care: Systematic review and meta-analysis. BMJ. 361:k14502018. View Article : Google Scholar : PubMed/NCBI

3 

Neubauer S, Zeidler J, Schilling T, Engel S, Linder R, Verheyen F, Haverich A and von der Schulenburg JG: Suitability and usability of claims data for review of guidelines for the treatment of chronic heart failure. Gesundheitswesen. 78:e135–e144. 2016.PubMed/NCBI

4 

McCormack PL: Sacubitril/valsartan: A review in chronic heart failure with reduced ejection fraction. Drugs. 76:387–396. 2016. View Article : Google Scholar : PubMed/NCBI

5 

Carvalho VO: Aerobic exercise prescription in patients with chronic heart failure: A review in the beta-blocker era. J Cardiovasc Med (Hagerstown). 13:570–574. 2012. View Article : Google Scholar : PubMed/NCBI

6 

Augustin U and Henschke C: Does telemonitoring lead to health and economic benefits in patients with chronic heart failure? -a systematic review. Gesundheitswesen. 74:e114–121. 2012.(In German). PubMed/NCBI

7 

Zhang X, Ma LL, Yao DK and Wang LX: Prediction values of T wave alternans for sudden cardiac death in patients with chronic heart failure: A brief review. Congest Heart Fail. 17:152–156. 2011. View Article : Google Scholar : PubMed/NCBI

8 

Antoniadis AP, Sieniewicz B, Gould J, Porter B, Webb J, Claridge S, Behar JM and Rinaldi CA: Updates in cardiac resynchronization therapy for chronic heart failure: Review of multisite pacing. Curr Heart Fail Rep. 14:376–383. 2017. View Article : Google Scholar : PubMed/NCBI

9 

Antoniadis AP, Sieniewicz B, Gould J, Porter B, Webb J, Claridge S, Behar JM and Rinaldi CA: Erratum to: Updates in cardiac resynchronization therapy for chronic heart failure: Review of multisite pacing. Curr Heart Fail Rep. 14:3842017. View Article : Google Scholar : PubMed/NCBI

10 

Health Quality Ontario: Effect of early follow-up after hospital discharge on outcomes in patients with heart failure or chronic obstructive pulmonary disease: A systematic review. Ont Health Technol Assess Ser. 17:1–37. 2017.

11 

Wang W, Jiang T, Li C, Chen J, Cao K, Qi LW, Li P, Zhu W, Zhu B and Chen Y: Will testosterone replacement therapy become a new treatment of chronic heart failure? A review based on 8 clinical trials. J Thorac Dis. 8:E269–E277. 2016. View Article : Google Scholar : PubMed/NCBI

12 

Vongmany J, Hickman LD, Lewis J, Newton PJ and Phillips JL: Anxiety in chronic heart failure and the risk of increased hospitalisations and mortality: A systematic review. Eur J Cardiovasc Nurs. 15:478–485. 2016. View Article : Google Scholar : PubMed/NCBI

13 

Siouta N, van Beek K, Preston N, Hasselaar J, Hughes S, Payne S, Garralda E, Centeno C, van der Eerden M, Groot M, et al: Towards integration of palliative care in patients with chronic heart failure and chronic obstructive pulmonary disease: A systematic literature review of European guidelines and pathways. BMC Palliat Care. 15:182016. View Article : Google Scholar : PubMed/NCBI

14 

Webb N, Cowie MR, Taylor M, Briggs A, Cohen A, de Pouvourville G, Haroun R, Trueman D and Deschaseaux C: The cost-effectiveness of treatment for chronic heart failure: A systematic review. Value Health. 18:A3912015. View Article : Google Scholar

15 

Kane PM, Murtagh FE, Ryan K, Mahon NG, McAdam B, McQuillan R, Ellis-Smith C, Tracey C, Howley C, Raleigh C, et al: The gap between policy and practice: A systematic review of patient-centred care interventions in chronic heart failure. Heart Fail Rev. 20:673–687. 2015. View Article : Google Scholar : PubMed/NCBI

16 

Macdonald PS: Combined angiotensin receptor/neprilysin inhibitors: A review of the new paradigm in the management of chronic heart failure. Clin Ther. 37:2199–2205. 2015. View Article : Google Scholar : PubMed/NCBI

17 

Shochat MK, Shotan A, Blondheim DS, Kazatsker M, Dahan I, Asif A, Rozenman Y, Kleiner I, Weinstein JM, Frimerman A, et al: Non-invasive lung IMPEDANCE-guided preemptive treatment in chronic heart failure patients: A randomized controlled trial (IMPEDANCE-HF Trial). J Card Fail. 22:713–722. 2016. View Article : Google Scholar : PubMed/NCBI

18 

Kervadec A, Bellamy V, El Harane N, Arakélian L, Vanneaux V, Cacciapuoti I, Nemetalla H, Périer MC, Toeg HD, Richart A, et al: Cardiovascular progenitor-derived extracellular vesicles recapitulate the beneficial effects of their parent cells in the treatment of chronic heart failure. J Heart Lung Transplant. 35:795–807. 2016. View Article : Google Scholar : PubMed/NCBI

19 

Markgren R, Brännström M, Lundgren C and Boman K: Impacts of person-centred integrated chronic heart failure and palliative home care on pharmacological heart failure treatment: A substudy of a randomised trial. BMJ Support Palliat Care. 9:e102016. View Article : Google Scholar : PubMed/NCBI

20 

Zhang H, Liu Y, Lao M, Ma Z and Yi X: Puerarin protects Alzheimer's disease neuronal cybrids from oxidant-stress induced apoptosis by inhibiting pro-death signaling pathways. Exp Gerontol. 46:30–37. 2011. View Article : Google Scholar : PubMed/NCBI

21 

Zhu G, Wang X, Chen Y, Yang S, Cheng H, Wang N and Li Q: Puerarin protects dopaminergic neurons against 6-hydroxydopamine neurotoxicity via inhibiting apoptosis and upregulating glial cell line-derived neurotrophic factor in a rat model of Parkinson's disease. Planta Med. 76:1820–1826. 2010. View Article : Google Scholar : PubMed/NCBI

22 

Qin F, Huang X, Zhang HM and Ren P: Pharmacokinetic comparison of puerarin after oral administration of Jiawei-Xiaoyao-San to healthy volunteers and patients with functional dyspepsia: Influence of disease state. J Pharm Pharmacol. 61:125–129. 2009. View Article : Google Scholar : PubMed/NCBI

23 

Duan S, Li YF and Luo XL: Effect of puerarin on heart function and serum oxidized-LDL in the patients with chronic cardiac failure. Hunan Yi Ke Da Xue Xue Bao. 25:176–178. 2000.(In Chinese). PubMed/NCBI

24 

He H, Shi M, Yang J, Zeng X, Qiao H, Wu L and Li L: The correlation between angiogenesis and abnormal expression of SERCA2a, phospholamban and the endothelin pathway in heart failure, and improvement by puerarin. Phytother Res. 22:948–956. 2008. View Article : Google Scholar : PubMed/NCBI

25 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

26 

Liu B, Zhao C, Li H, Chen X, Ding Y and Xu S: Puerarin protects against heart failure induced by pressure overload through mitigation of ferroptosis. Biochem Biophys Res Commun. 497:233–240. 2018. View Article : Google Scholar : PubMed/NCBI

27 

Zhirov IV, Zaseeva AV, Masenko VP and Tereshchenko SN: Peroxisome proliferator-activated receptors-alpha (PPAR-alpha) and chronic heart failure: Is there a reason to discuss the metabolic strategy of treatment? Ter Arkh. 86:78–82. 2014.(In Russian). PubMed/NCBI

28 

Fu YH, Lin QX, Li XH, Fei HW, Shan ZX, Huang XZ, Liu XY, Yang M, Lin SG, Zhou SF, et al: A novel rat model of chronic heart failure following myocardial infarction. Methods Find Exp Clin Pharmacol. 31:367–373. 2009.PubMed/NCBI

29 

Zhao W, Liu L, Wang Y, Mao T and Li J: Effects of a combination of puerarin, baicalin and berberine on the expression of proliferator-activated receptor-γ and insulin receptor in a rat model of nonalcoholic fatty liver disease. Exp Ther Med. 11:183–190. 2016. View Article : Google Scholar : PubMed/NCBI

30 

Kirk RGW: Recovering the principles of humane experimental technique: The 3Rs and the human essence of animal research. Sci Technol Human Values. 43:622–648. 2018. View Article : Google Scholar : PubMed/NCBI

31 

Dergilev KV, Tsokolaeva ZI, Rubina KA, Sysoeva VY, Makarevich PI, Boldyreva MA, Beloglazova IB, Zubkova ES, Sharonov GV, Akchurin RS and Parfyonova YV: Isolation and characterization of cardiac progenitor cells obtaining from myocardial right atrial appendage tissue. Tsitologiia. 58:340–348. 2016.(In English, Russian). PubMed/NCBI

32 

Sun WP, Lu YX, Zhang XY, Tang WW and Huang QY: Effects of cocaine on activities of ATPase, LDH and SDH in mouse splenocytes. Fa Yi Xue Za Zhi. 26:81–83. 2010.(In Chinese). PubMed/NCBI

33 

Lin MH, Yuan WL, Huang TC, Zhang HF, Mai JT and Wang JF: Clinical effectiveness of telemedicine for chronic heart failure: A systematic review and meta-analysis. J Investig Med. 65:899–911. 2017. View Article : Google Scholar : PubMed/NCBI

34 

Yohannes AM, Chen W, Moga AM, Leroi I and Connolly MJ: Cognitive impairment in chronic obstructive pulmonary disease and chronic heart failure: A systematic review and meta-analysis of observational studies. J Am Med Dir Assoc. 18:451 e451–451 e411. 2017. View Article : Google Scholar

35 

Crowley MJ, Diamantidis CJ, McDuffie JR, Cameron CB, Stanifer JW, Mock CK, Wang X, Tang S, Nagi A, Kosinski AS and Williams JW Jr: Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: A systematic review. Ann Intern Med. 166:191–200. 2017. View Article : Google Scholar : PubMed/NCBI

36 

Heather LC, Pates KM, Atherton HJ, Cole MA, Ball DR, Evans RD, Glatz JF, Luiken JJ, Griffin JL and Clarke K: Differential translocation of the fatty acid transporter, FAT/CD36, and the glucose transporter, GLUT4, coordinates changes in cardiac substrate metabolism during ischemia and reperfusion. Circ Heart Fail. 6:1058–1066. 2013. View Article : Google Scholar : PubMed/NCBI

37 

Tziakas D, Chalikias G, Parissis JT, Hatzinikolaou H, Stakos D, Papadopoulou E, Kortsaris A and Hatseras D: Prolonged activation of tumor necrosis factor (TNF)-alpha and its soluble receptors in chronic heart failure patients both in the compensated and decompensated state. Interplay between their levels and metalloproteinase-3. Eur Cytokine Netw. 15:231–239. 2004.PubMed/NCBI

38 

Adamopoulos S, Parissis JT and Kremastinos DT: A glossary of circulating cytokines in chronic heart failure. Eur J Heart Fail. 3:517–526. 2001. View Article : Google Scholar : PubMed/NCBI

39 

Afanasiev SA, Egorova MV, Kondratyeva DS, Batalov RE and Popov SV: Comparative analysis of changes of myocardial angiogenesis and energy metabolism in postinfarction and diabetic damage of rat heart. J Diabetes Res. 2014:8278962014. View Article : Google Scholar : PubMed/NCBI

40 

Amani M, Jeddi S, Ahmadiasl N, Usefzade N and Zaman J: Effect of HEMADO on level of CK-MB and LDH enzymes after ischemia/reperfusion injury in isolated rat heart. Bioimpacts. 3:101–104. 2013.PubMed/NCBI

41 

Cheng W, Wu P, Du Y, Wang Y, Zhou N, Ge Y and Yang Z: Puerarin improves cardiac function through regulation of energy metabolism in Streptozotocin-Nicotinamide induced diabetic mice after myocardial infarction. Biochem Biophys Res Commun. 463:1108–1114. 2015. View Article : Google Scholar : PubMed/NCBI

42 

Schaun MI, Marschner RA, Peres TR, Markoski MM and Lehnen AM: Aerobic training prior to myocardial infarction increases cardiac GLUT4 and partially preserves heart function in spontaneously hypertensive rats. Appl Physiol Nutr Metab. 42:334–337. 2017. View Article : Google Scholar : PubMed/NCBI

43 

Bodart V, Febbraio M, Demers A, McNicoll N, Pohankova P, Perreault A, Sejlitz T, Escher E, Silverstein RL, Lamontagne D and Ong H: CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res. 90:844–849. 2002. View Article : Google Scholar : PubMed/NCBI

44 

Haemmerle G, Moustafa T, Woelkart G, Büttner S, Schmidt A, van de Weijer T, Hesselink M, Jaeger D, Kienesberger PC, Zierler K, et al: ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-α and PGC-1. Nat Med. 17:1076–1085. 2011. View Article : Google Scholar : PubMed/NCBI

45 

Muoio DM, MacLean PS, Lang DB, Li S, Houmard JA, Way JM, Winegar DA, Corton JC, Dohm GL and Kraus WE: Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) alpha knock-out mice. Evidence for compensatory regulation by PPAR delta. J Biol Chem. 277:26089–26097. 2002. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

November 2019
Volume 18 Issue 5

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
He, L., Wang, T., Chen, B., Lu, F., & Xu, J. (2019). Puerarin inhibits apoptosis and inflammation in myocardial cells via PPARα expression in rats with chronic heart failure. Experimental and Therapeutic Medicine, 18, 3347-3356. https://doi.org/10.3892/etm.2019.7984
MLA
He, L., Wang, T., Chen, B., Lu, F., Xu, J."Puerarin inhibits apoptosis and inflammation in myocardial cells via PPARα expression in rats with chronic heart failure". Experimental and Therapeutic Medicine 18.5 (2019): 3347-3356.
Chicago
He, L., Wang, T., Chen, B., Lu, F., Xu, J."Puerarin inhibits apoptosis and inflammation in myocardial cells via PPARα expression in rats with chronic heart failure". Experimental and Therapeutic Medicine 18, no. 5 (2019): 3347-3356. https://doi.org/10.3892/etm.2019.7984